Conjoint IGF-I and insulin infusion shows diverse interactive effects in diabetic rats.

Tomas FM, Knowles SE, Owens PC, Burgoyne JL, Chandler CS, Ballard FJ

Diabetes1 Feb 1996Cited by 10 (Europe PMC)

PMID8549861DOI10.2337/diab.45.2.170PepBankPUB-08549861

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, des(1‑3)IGF-I increased body weight gain compared with controls.
In plain wordsIn rats with diabetes, des(1‑3)IGF-I increased weight gain compared with controls.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseBody weight gain
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Comparator
Controls
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · infusion · 7 daysAs given in this study (rat).
Measurements
Increase in body weight gain
7 g/day
des(1-3)IGF-I compared with controls
Body weight gain
1.2 g/day
controls
Source sentences
Summary
Both insulin and des(1-3)IGF-I increased body weight gain by 7 g/day compared with controls (1.2 g/day), but there was no additive effect.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
Report a problemFND-0854986101
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, des(1‑3)IGF-I increased nitrogen retention additively with 2.2 nmol/day insulin.
In plain wordsIn rats with diabetes, adding des(1‑3)IGF-I to 2.2 nmol/day insulin increased nitrogen retention.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseNitrogen retention with insulin
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Comparator
2.2 nmol/day insulin alone
Outcome group
Muscle injury and repair · Musculoskeletal
Studied dose
Dose not stated · infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
However, for nitrogen retention, the effects of des(1-3)IGF-I were additive with those of 2.2 nmol/day insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
Report a problemFND-0854986103
03AnimalAnimal study (in vivo)Activity measurement
In diabetic rats, des(1‑3)IGF-I was two- to threefold more potent than IGF-I.
In plain wordsIn rats with diabetes, des(1‑3)IGF-I was more potent than IGF-I.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseRelative potency
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Comparator
IGF-I
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated · infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
Des(1-3)IGF-I was two- to threefold more potent than IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
Report a problemFND-0854986104
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, des(1‑3)IGF-I increased liver glycogen additively with insulin.
In plain wordsIn rats with diabetes, adding des(1‑3)IGF-I to insulin increased liver glycogen.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseLiver glycogen
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Comparator
Insulin alone
Outcome group
Glycemic control · Liver
Studied dose
Dose not stated · infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
Des(1-3)IGF-I increased liver glycogen additively with insulin
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
Report a problemFND-0854986107
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rats, des(1‑3)IGF-I reduced glucosuria only when given with 5.6 nmol insulin per day.
In plain wordsIn rats with diabetes, des(1‑3)IGF-I reduced urine glucose only with the specified insulin dose.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseGlucosuria with insulin
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 7 daysAs given in this study (rat).
Source sentences
Summary
Des(1-3)IGF-I increased liver glycogen additively with insulin but reduced glucosuria only when given with 5.6 nmol insulin per day, indicating the possibility of a facilitatory effect, perhaps via increased insulin sensitivity.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
Report a problemFND-0854986108

Studies that did not test the peptide alone5

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

06AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, combined insulin and des(1‑3)IGF-I produced no additive effect on body weight gain.
In plain wordsIn rats with diabetes, combined insulin and des(1‑3)IGF-I produced no additive weight gain.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
No significant changeAdditive body weight gain
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Both insulin and des(1-3)IGF-I increased body weight gain by 7 g/day compared with controls (1.2 g/day), but there was no additive effect.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0854986102
07AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats with comparable total nitrogen retention, pooled IGF treatment produced lower carcass nitrogen retention than insulin.
In plain wordsIn rats with diabetes, pooled IGF treatment produced lower carcass nitrogen retention than insulin at comparable total retention.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseCarcass nitrogen retention
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Comparator
Insulin
Outcome group
Muscle injury and repair · Musculoskeletal
Source sentences
Summary
At comparable rates of total nitrogen retention, carcass nitrogen retention was approximately 35% higher with insulin than with IGF treatment, indicating a differential tissue response.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0854986105
08AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, pooled IGF treatments did not alter carcass fat content.
In plain wordsIn rats with diabetes, pooled IGF treatments did not change carcass fat content.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
No significant changeCarcass fat content
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
IGFs did not alter carcass fat content.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0854986106
09AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Activity measurement
In diabetic rats, IGF treatments had lower glucoregulatory potency than insulin.
In plain wordsIn rats with diabetes, pooled IGF treatments had lower glucose-regulating potency than insulin.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseGlucoregulatory potency
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Comparator
Insulin
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin was 10- to 25-fold more potent in these glucoregulatory actions.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0854986109
10AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rats, the hormones produced differential effects on kidney, liver, and thymus weights without specified directions.
In plain wordsIn rats with diabetes, hormone effects differed for organ weights, but the abstract did not state the directions.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Direction not reportedOrgan weights
Study
ratn: not reported in source
Streptozotocin-induced diabetes
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
Differential effects of the hormones were also observed for kidney, liver, and thymus weights.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the efficacy of IGFs as an adjunct treatment with insulin in diabetes, we infused IGF-I or des(1-3)IGF-I for 7 days at 0, 10.7, 26.7, and 66.8 nmol/day to streptozotocin-induced diabetic rats in conjunction with infusions of 0, 2.2, 5.6, or 14 nmol/day insulin.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0854986110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 2
21 Oct 2026, 13:52 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.